Supracricoid laryngectomy with cricohyoidopexy: oncological results

Abstract

This study assessed the oncological results in patients undergoing supracricoid laryngectomy with cricohyoidopexy. A cohort of 44 patients surgically treated using supracricoid laryngectomy with cricohyoidopexy between June 2001 and December 2009 was retrospectively analyzed. The mean follow-up period was 53.2 (±24.7) months. The Kaplan-Meier method was used to analyze overall survival and disease-specific survival, as well as survival according to T2 and T3 subgroups. Overall survival rates at 3 and 5 years were 90.5 and 84.1%, respectively. The 3- and 5-year disease-specific survival rates were 95.4 and 92.5%, respectively. Overall survival for patients with T2 disease was 87.5% at 3 years and 80.8% at 5 years. For T3, the corresponding rates were 91.8 and 87.0%. Disease-specific survival for patients with T2 disease was 93.3% at 3 years and the same at 5 years; the corresponding rates for T3 were 96.4 and 91.4%. The differences between T2 and T3 patients at 3 and 5 years with respect to overall and disease-specific survival were not statistically significant (P = 0.903 and P = 0.863, respectively). Recurrence was local in one patient (2.2%) and regional in three (6.8%). There were three distant metastases (6.8%) and one second primary carcinoma (2.2%). These findings support the use of supracricoid laryngectomy with cricohyoidopexy as an oncologically safe technique in properly selected patients with laryngeal carcinoma.

Modified supracricoid laryngectomy: oncological and functional outcomes in the elderly

“…The decannulation rate was 90.5%, which is similar to that reported in the literature (Gallo et al13 reported 92%, Sanchez-Cuadrado15 reported 97%, and Topaloğlu et al3 reported 100%). All patients had a normal diet, and gastrostomy was not used (versus 2% reported in a literature review19).…”

“…The nasogastric feeding tube was removed after a mean of 19 days, which is a similar or shorter period than that reported in the literature (Gallo et al13 reported 19 days, Sanchez-Cuadrado14 reported 18 days, Topaloğlu et al3 reported 29.3 days, and Gonçalves et al16 reported 2.3 months). This outcome can be attributed to both arytenoid preservation and neoglottis reconstruction.…”

“…Our oncological results are similar to those reported in the literature, even though our sample was small. Gallo et al13 reported locoregional recurrence in 8.7% of 234 patients who underwent SCL with CHP or CHEP, Sanchez-Cuadrado et al15 reported locoregional recurrence in 25% of 41 patients treated by SCL with CHP or CHEP, Gonçalves et al16 reported locoregional recurrence in 5% of 20 patients treated by SCL, and Topaloğlu et al3 reported locoregional recurrence in 2.2% of 44 patients who underwent SCL with CHP. Furthermore, in our study, there were no distant metastases or second tumors, probably because of the restrictive selection criteria for modified SCL.…”

“…SCL is widely used in Europe and has reduced the indications for total laryngectomy. Recent reports3–5 indicate that SCL has also been applied in selected advanced laryngeal cancer and after radiotherapy failure.…”

Oncological Outcomes of Primary vs. Salvage OPHL Type II: A Systematic Review

“…Eight articles assessed the oncological outcome of OPHL type II combined with adjuvant radiotherapy [8,13,[22][23][24][25][26][27] (Table 3). Overall, adjuvant RT proved to be adequate for: positive resection margin, thyroid cartilage invasion (stage T4a), positive neck nodes with extracapsular invasion, multiple nodal metastases, following the National Comprehensive Cancer Network (NCCN) [28] guidelines.…”